Document is current
Any future updates will be listed below
-
Authors
Cole, Michelle J. https://orcid.org/0000-0002-6707-6910
Quaye, Nerteley
Jacobsson, Susanne
Day, Michaela
Fagan, Elizabeth
Ison, Catherine
Pitt, Rachel
Seaton, Shila
Woodford, Neil
Stary, Angelika
Pleininger, Sonja
Crucitti, Tania
Hunjak, Blaženka
Maikanti, Panayiota
Hoffmann, Steen
Viktorova, Jelena
Buder, Susanne
Kohl, Peter
Tzelepi, Eva
Siatravani, Eirini
Balla, Eszter
Hauksdóttir, Guðrún Svanborg
Rose, Lisa
Stefanelli, Paola
Carannante, Anna
Pakarna, Gatis
Mifsud, Francesca
Cassar, Rosann Zammit
Linde, Ineke
Bergheim, Thea
Steinbakk, Martin
Mlynarczyk-Bonikowska, Beata
Borrego, Maria-José
Shepherd, Jill
Pavlik, Peter
Jeverica, Samo
Vazquez, Julio
Abad, Raquel
Weiss, Sabrina
Spiteri, Gianfranco
Unemo, Magnus
-
Funding
Funding for this research was provided by:
European Centre for Disease Prevention and Control (ECDC/2013/015)
- License Information
-
More Information
Article History
Received: 8 January 2019
Accepted: 12 March 2019
First Online: 25 March 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The authors declare that they have no competing interests. However, PHE’s AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Accelerate Diagnostics, Achaogen Inc., Allecra Therapeutics, Amplex, AstraZeneca UK Ltd., AusDiagnostics, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, Food Standards Agency, GlaxoSmithKline Services Ltd., Helperby Therapeutics, Henry Stewart Talks, IHMA Ltd., Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp., Meiji Seika Pharma Co. Ltd., Mobidiag, Momentum Biosciences Ltd., Neem Biotech, Nordic Pharma Ltd., Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd., Roche, Rokitan Ltd., Smith & Nephew UK Ltd., Shionogi & Co. Ltd., Speedx, Trius Therapeutics, VenatoRx Pharmaceuticals and Wockhardt Ltd.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
